Newer Biologics for the Treatment of Plaque Psoriasis


( Last Updated : September 23, 2021)
Project Line:
Health Technology Review
Project Sub Line:
Rapid Review
Project Number:
RC1377-000

Details


Question

  1. ​What is the clinical effectiveness of newer biologics compared to older biologics in patients with plaque psoriasis? ​​

Key Message

  • Eight systematic reviews with network meta-analysis were identified that compared newer biologics with older biologics in patients with moderate-to-severe plaque psoriasis. There was extensive overlap of primary studies across the systematic reviews and network meta-analyses.
  • Newer biologics such as secukinumab, ixekizumab, brodalumab and risankizumab were more favourable compared to older biologics (adalimumab, etanercept, and ustekinumab) in reaching 90% or 100% skin clearance, as measured with the Psoriasis Area Severity Index. The risk of side effects was similar between the newer and older biologics.​